SCHEMBL2232189

SCHEMBL2232189

CCCCC([C]=O)N(C)C

nearest known ligand 0.36

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 2/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
FDPS P14324 1/20 0.33
CA2 P00918 3/20 0.32
MAPK1 P28482 1/20 0.32
CA1 P00915 1/20 0.31
MAPT P10636 1/20 0.30
ALDH1A1 P00352 2/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231053 0.85
SCHEMBL15529854 0.77 CHRM2 (0.34)
SCHEMBL9333404 0.76 TSHR (0.40) DNM1TSHRALDH1A1TDP1
SCHEMBL2234480 0.74
SCHEMBL831724 0.70
SCHEMBL28839031 0.70 RNPEP (0.34)
SCHEMBL1080981 0.69 DNM1 (0.39) DNM1TSHRSMN1; SMN2FDPSCA2
SCHEMBL5880658 0.69
SCHEMBL534991 0.68 GABRP (0.41) MAPT
SCHEMBL9333397 0.68 TSHR (0.37) DNM1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2846823-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES Novo Nordisk A/S (DK) 2015-03-18 EP disclosed
US-20140128399-A1 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP DUKE UNIVERSITY (US) 2014-05-08 US disclosed
WO-2013167454-A1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 2013-11-14 WO disclosed
US-20110171195-A1 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP DUKE UNIVERSITY (US) 2011-07-14 US disclosed
WO-2008157205-A2 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP DUKE UNIVERSITY (US) 2008-12-24 WO disclosed
US-5789439-A SKIN ULCERS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1998-08-04 US disclosed
EP-0448029-B1 Novel pharmaceutical uses of forskolin derivatives NIPPON KAYAKU KK (JP) 1995-12-20 EP disclosed
EP-0650723-A2 Novel pharmaceutical use of forskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1995-05-03 EP disclosed
EP-0448029-A2 Novel pharmaceutical uses of forskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1991-09-25 EP disclosed
EP-0297496-A2 Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1989-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171195-A1 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP PDE7A, PDE8A, PDE8B DNM1 1150/4885TSHR 4054/4885SMN1; SMN2 4450/4885
US-20140128399-A1 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP PDE7A, PDE8A, PDE8B DNM1 1150/4885TSHR 4054/4885SMN1; SMN2 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.